Custom Software for Biotech — Validated, Auditable, Built to Survive Inspection

In most industries a deploy is a deploy. In FDA-regulated life sciences, a system that creates, modifies, or stores GxP records lives under 21 CFR Part 11, and the software has to be validated — proven fit for its intended use and kept in that state through change control. A contractor who has never read a validation plan will ship something that works in a demo and fails the first data-integrity inspection.

We build with that reality in the first architecture diagram. Records are attributable to an authenticated identity with no shared logins. Audit trails are sequenced, immutable, and reviewable. Timestamps come from a trusted clock, not the user's browser. Electronic signatures carry the signer's printed name, the date and time, and the meaning of the signature. The validation strategy — risk-based, in line with the FDA's Computer Software Assurance guidance — is decided before code is written, so your QA team inherits a system that survives audit instead of one that triggers a remediation project.

Most industries deal with one or two overlapping frameworks. A life-sciences product routinely sits at the intersection of several. A single study portal that collects consent, captures lab results from a LIMS, and feeds a CTMS can simultaneously touch 21 CFR Part 11 for the electronic records, GCP for the trial conduct, HIPAA for the subject data, and the Common Rule and IRB oversight if the research is federally funded. Add a European site and EU Annex 11 and GDPR join the stack.

The integration surface is the other hard part. LIMS platforms like LabWare, STARLIMS, Benchling, and LabVantage; ELN systems; instruments that speak SiLA 2, OPC-UA, or a proprietary file drop onto a network share; EDC and CTMS systems; and clinical data standards like CDISC SDTM and ADaM. Each has its own quirks, its own validated state to preserve, and its own failure mode when an overnight batch silently drops a record. We have wired ingestion pipelines, chain-of-custody trackers, and audit-grade data layers before, and we know where the time gets eaten — usually in vendor onboarding and in proving data lineage, not in the UI.

21 CFR Part 11. The baseline for electronic records and signatures in FDA-regulated work. We implement unique authenticated identities, sequenced and immutable audit trails, record protection against silent overwrite, signature manifestation, and the operational controls Part 11 expects — account lockout, session timeout, and authority checks. Each control is documented for your validation package.

GxP and GAMP 5 / CSA. Good Laboratory, Clinical, and Manufacturing Practice all shape how software is validated. We follow GAMP 5 second edition and the FDA's Computer Software Assurance guidance — a risk-based, critical-thinking-led approach that focuses testing where patient safety and data integrity actually live, rather than scripting every screen. You get a requirements trace matrix, risk assessment, targeted IQ/OQ/PQ, and a validation summary.

Data integrity (ALCOA+). Inspectors evaluate records against ALCOA+ principles. We build attribution, contemporaneous trusted timestamps, preserved originals, and reviewable, exportable audit trails so the data lineage holds up from raw instrument output to final record.

HIPAA and the Common Rule. When identifiable human-subject data is involved, HIPAA applies, and federally funded research adds Common Rule and IRB obligations. We encrypt PHI at rest with envelope keys, scope access by site and study, log disclosures, and sign a BAA where appropriate, coordinating with your privacy officer and IRB.

EU Annex 11 and GDPR. If trials or operations cross into the EU, Annex 11 mirrors Part 11 for computerized systems and GDPR governs personal data. We build encryption, access control, and data-subject-rights handling that satisfy both regimes with one architecture rather than two parallel builds.

SOC 2 and vendor diligence. Pharma and CRO partners increasingly run security questionnaires before they connect to your systems. We build with SOC 2 Common Criteria in mind — encryption, RBAC, change management, audit logging, and incident response — so the diligence is an evidence exercise, not a scramble.

Next.js 16 on the App Router with React 19 and TypeScript end to end. Postgres as the validated system of record — usually Neon, Supabase, or RDS depending on BAA needs and the compliance posture — with Prisma or Drizzle as the type-safe ORM. Sensitive columns get KMS-backed envelope encryption, and audit trails live in a separate append-only store so they cannot be edited in place. Resend handles transactional email with a verified domain and DMARC alignment.

For instrument and integration work we lean Python on the ingestion side — file watchers, SiLA 2 clients, or vendor SDKs feeding a FastAPI or queue-backed pipeline (Inngest or BullMQ on Redis), with checksums and structured logging at every hop so data lineage is provable. A TypeScript dashboard sits over the top for human review and sign-off. Auth uses Auth0, Clerk, or a Lucia-style stack with MFA required on every record-creating surface and no shared accounts, which Part 11 forbids. Observability runs through Sentry plus a log aggregator (Datadog or Better Stack) with PII/PHI-aware redaction in the logger. The web tier deploys to Vercel; the data plane runs in a hardened VPC when BAA or validation scope requires it.

Three patterns repeat. First, the audit trail is bolted on after launch. A team ships a lab tool, then learns during the first data-integrity review that it cannot reconstruct who changed a result or when. Retro-fitting an immutable, sequenced audit trail means re-instrumenting every write path. Build the audit trail first, not last.

Second, validation is treated as a documentation task at the end. The system gets built like any web app, and then someone is asked to validate it after the fact — discovering that shared logins, editable timestamps, and silent overwrites are baked into the design. Validation is an architecture decision made on day one, not a binder assembled in week twenty.

Third, instrument and LIMS integration scope is underestimated. A founder assumes the instrument has a clean API and the LIMS sync is a sprint. The reality is proprietary file formats, vendor onboarding that takes weeks, and uneven sandbox parity. We pad those timelines and start vendor coordination the week the contract signs, because that is where life-sciences builds actually slip.

The asset in biotech is the science and the data — assay protocols, sequence data, formulation parameters, and the validated software that orchestrates them. The quiet existential risk is not a bug; it is your core IP sitting on a foreign contractor's laptop, or a validated system silently broken by an undocumented change. That is precisely why we are US-based, founder-led, and engagement-first on every project.

William Beltz writes or reviews every line of code that touches your records, your samples, or your subject data. NDAs are mutual and signed before discovery. Source code lives in your GitHub organization, not ours. Changes are documented and change-controlled so your validated state holds, and the handoff is documented for either ongoing collaboration or in-house ownership — your call.

Biotech is a documented target for nation-state IP theft — research data, trial results, and manufacturing know-how are strategic — alongside the ransomware affiliates that hit every sector. We run MITRE ATT&CK-aligned assessments that simulate those groups' documented TTPs against your environment, then deliver an ATT&CK heatmap of which techniques succeed, which get detected, and which get blocked.

Standard penetration testing covers the rest — external perimeter, web application, and API surface — with reporting that supports your security questionnaires and cyber-insurance requirements. For labs running their own domain, our Active Directory pentest walks the full chain from a standard workstation to Domain Admin, with every step mapped to ATT&CK technique IDs your SOC or MSSP can alert on.

QUANT LAB USA does not yet have a published biotech case study, and we are saying that plainly rather than inventing one. What we have is the audit-grade architecture pattern — authenticated identity, immutable audit trails, validated data lineage, encryption, and ATT&CK-aligned pentesting — that other regulated domains already run on in production, including healthcare back-office systems with auditable record handling.

A discovery engagement for biotech starts with a validation and data-integrity review — your intended use, your regulatory scope, your existing instruments and LIMS, and the records that have to survive inspection. You come out with a wireframed UI, a data model with record boundaries and audit points marked, a validation strategy, and a phased estimate — useful even if you take it to another developer.